Biomerix Corporation and Gel Company today announced a strategic distribution agreement for the Biomerix 3D Scaffold, a novel three-dimensional tissue scaffold. Under the agreement, Gel Company will market and distribute the Biomerix 3D Scaffold to researchers in the life science community across the United States.
The Biomerix 3D Scaffold consists of a non-degradable, open-cell polycarbonate polyurethane, designed to mimic the nature and function of the extracellular matrix (ECM). Its unique three-dimensional microarchitecture embodies a network of interconnecting cells and pores constructed to support tissue ingrowth, allowing researchers to study cells in an environment that simulates the conditions of cells in the body. The unique chemistry and macroporous structure of the Biomerix 3D Scaffold supports the growth of myriad cell types and delivers more predictive results compared to standard 2D cell culture systems. The proprietary Biomerix Biomaterial, used to manufacture the Biomerix 3D Scaffold has been demonstrated to support optimal cell proliferation and superior cell viability in both in-vitro and in-vivo studies and has received seven US and international regulatory clearances for a variety of indications.
"We have already experienced interest in the Biomerix 3D Scaffold, and we are delighted to add this innovative technology to our portfolio of products," said Greg Richardson, President of the Gel Company. "The Biomerix 3D Scaffold is an excellent fit with our expertise in the life science research community."
"Biomerix is very pleased to have the Gel Company become one of our distribution partners. Their reputation as a quality supplier, as well as their commitment to customer service, was appealing to Biomerix," stated Kenneth Hayes, President and Chief Executive Officer of Biomerix Corporation. "We look forward to a long and prosperous partnership with the Gel Company."